Newcastle cancer trial saves Scottish teenager's life after relapse

A Scottish teenager from North Ayrshire is currently cancer-free and celebrating his eighteenth birthday following a pioneering clinical trial at the Great North Children’s Hospital, according to regional reporting. Noah Hyslop initially sought medical attention for leg pain that he assumed was a routine stress fracture, but medical evaluations revealed a diagnosis of Ewing sarcoma, a rare cancer affecting bones and soft tissue. Following intensive rounds of conventional treatment involving chemotherapy and radiotherapy, the young patient experienced temporary remissions, but the disease tragically returned multiple times, eventually spreading to his lungs by December 2025. After his hospital consultant in Glasgow connected the family with an ongoing study across the border, the teenager began receiving an experimental drug combination in February 2026 that has left him with no current sign of tumours.

The medical journey began in September 2023 when Noah attended hospital with leg pain, mistakenly believing he had sustained a stress fracture, as detailed by the Yahoo News UK report. After undergoing multiple rounds of chemotherapy and radiation therapy at a hospital in Glasgow, he achieved remission by July 2024. However, subsequent relapses tested the family's resilience. According to the Daily Record coverage, shoulder pain in January 2025 signalled the first return of the disease, which briefly stabilised after a trial in Glasgow before returning aggressively in December 2025 with tumours discovered in his lungs.

Media additions

Faced with limited conventional options, Noah's family received a timely intervention when his Glasgow consultant informed them of a specialised trial taking place in Newcastle. Commencing treatment in February 2026, the teenager has since completed several cycles of the regimen. Reporting from Chronicle Live highlights that the experimental protocol involves an antibody drug designed to target a specific protein known as a 'death cell receptor' (DR 5). This mechanism plays a critical role in clearing abnormal or damaged cells from the body, and researchers deploy it alongside two established chemotherapy medicines already approved for clinical use in the UK.

Medical professionals involved in the multi-centre international study have expressed optimism regarding the preliminary outcomes. Dr Quentin Campbell-Hewson, a consultant paediatric oncologist at the Great North Children’s Hospital and associate lecturer at Newcastle University who leads the trial locally, noted that the protocol offers an important lifeline to patients with restricted choices. Professor Sandra Strauss, chief investigator for the trial and professor of medical and teenage and young adult oncology at the University College London Cancer Institute, emphasised that innovative treatments are urgently required to improve survival rates in rare cancers like Ewing sarcoma.

"The team at Newcastle is fabulous and without them I may not have made my 18th birthday in July this year. They really are life savers. The trial is truly amazing."

Noah Hyslop, Patient, via Yahoo News UK

Reflecting on the emotional toll of the ordeal, Noah's father, Paul Hyslop, described the initial diagnosis as a severe shock and admitted that the family feared reaching the milestone birthday might not be possible. Meanwhile, local medical experts continue to monitor the broader applications of the therapy.

As research progresses, the international study remains active across multiple global centres, evaluating efficacy and patient impact across various age groups. For the Hyslop family, the focus remains on the ongoing trial results as medical teams continue tracking the long-term effectiveness of the novel antibody combination.